[go: up one dir, main page]

Vandel et al., 1995 - Google Patents

Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients

Vandel et al., 1995

Document ID
12661721890073986666
Author
Vandel S
Bertschy G
Baumann P
Bouquet S
Bonin B
Francois T
Sechter D
Bizouard P
Publication year
Publication venue
Pharmacological research

External Links

Snippet

The in vivo pharmacokinetic interaction between two selective serotonin reuptake inhibitors (SSRI)(fluvoxamine, fluoxetine) and tricyclic antidepressants (TCAs)(amitriptyline, clomipramine) or neuroleptics (haloperidol, cyamemazine, levomepromazine …
Continue reading at www.sciencedirect.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline

Similar Documents

Publication Publication Date Title
Vandel et al. Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients
Hamelin et al. The disposition of fluoxetine but not sertraline is altered in poor metabolizers of debrisoquin
Cholerton et al. The role of individual human cytochrpmes P450 in drug metabolism and clinical response
Horikiri et al. Pharmacokinetics and metabolism of bisoprolol enantiomers in humans
AU774923B2 (en) Use of CYP2D6 inhibitors in combination therapies
Lalovic et al. Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes
Sindrup et al. Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms
Moody et al. The involvement of cytochrome P450 3A4 in the N-demethylation of L-α-acetylmethadol (LAAM), norLAAM, and methadone
Kobayashi et al. The effects of selective serotonin reuptake inhibitors and their metabolites on S‐mephenytoin 4'‐hydroxylase activity in human liver microsomes.
Prakash et al. Metabolism and excretion of a new antipsychotic drug, ziprasidone, in humans
Crewe et al. The effect of selective serotonin re‐uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes.
Postlind et al. Tolterodine, a new muscarinic receptor antagonist, is metabolized by cytochromes P450 2D6 and 3A in human liver microsomes
Brøsen The pharmacogenetics of the selective serotonin reuptake inhibitors
Dain et al. Biotransformation of clozapine in humans
Hamelin et al. In vitro characterization of cytochrome P450 2D6 inhibition by classic histamine H1 receptor antagonists
Mellström et al. Amitriptyline metabolism: association with debrisoquin hydroxylation in nonsmokers
Eap et al. Fluvoxamine and fluoxetine do not interact in the same way with the metabolism of the enantiomers of methadone
Shin et al. Potent inhibition of CYP2D6 by haloperidol metabolites: stereoselective inhibition by reduced haloperidol
Ching et al. Potent inhibition of yeast-expressed CYP2D6 by dihydroquinidine, quinidine, and its metabolites
Eap et al. Pharmacokinetics and pharmacogenetics of methadone: clinical relevance
Coutts Polymorphism in the metabolism of drugs, including antidepressant drugs: comments on phenotyping
Blake et al. Metabolism of thioridazine by microsomal monooxygenases: relative roles of P450 and flavin-containing monooxygenase
Muralidharan et al. Quinidine inhibits the 7-hydroxylation of chlorpromazine in extensive metabolisers of debrisoquine
Albers et al. Effect of venlafaxine on imipramine metabolism
Kajita et al. Effects of olopatadine, a new antiallergic agent, on human liver microsomal cytochrome P450 activities